A REVIEW of MODERN METHODS in HISTOCHEMISTRY on September 26, 2021 by Guest
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis
Journal of Allergy Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Guest Editors: Ralph Mösges, Carlos E. Baena-Cagnani, and Desiderio Passali Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Journal of Allergy Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Guest Editors: Ralph Mosges,¨ Carlos E. Baena-Cagnani, and Desiderio Passali Copyright © 2014 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Journal of Allergy.” All articles are open access articles distributed under the Creative Commons At- tribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board William E. Berger, USA Alan P. Knutsen, USA Fabienne Ranc, France Kurt Blaser, Switzerland Marek L. Kowalski, Poland Anuradha Ray, USA Eugene R. Bleecker, USA Ting Fan Leung, Hong Kong Harald Renz, Germany JandeMonchy,TheNetherlands Clare M Lloyd, UK Nima Rezaei, Iran Frank Hoebers, The Netherlands Redwan Moqbel, Canada Robert P. Schleimer, USA StephenT.Holgate,UK Desiderio Passali, Italy Massimo Triggiani, Italy Sebastian L. Johnston, UK Stephen P. Peters, USA Hugo Van Bever, Singapore Young J. Juhn, USA David G. Proud, Canada Garry Walsh, United Kingdom Contents Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis,RalphMosges,¨ Carlos E. Baena-Cagnani, and Desiderio Passali Volume 2014, Article ID 416236, 2 pages Clinical Efficacy of a Spray Containing Hyaluronic Acid and Dexpanthenol after Surgery in the Nasal Cavity (Septoplasty, Simple Ethmoid Sinus Surgery, and Turbinate Surgery), Ina Gouteva, Kija Shah-Hosseini, and Peter Meiser Volume 2014, Article ID 635490, 10 pages The Effectiveness of Acupuncture Compared to Loratadine in Patients Allergic to House Dust ,Mites Bettina Hauswald, Christina Dill, Jurgen¨ Boxberger, Eberhard Kuhlisch, Thomas Zahnert, and Yury M. -
The Morphology, Androgenic Function, Hyperplasia, and Tumors of the Human Ovarian Hilus Cells * William H
THE MORPHOLOGY, ANDROGENIC FUNCTION, HYPERPLASIA, AND TUMORS OF THE HUMAN OVARIAN HILUS CELLS * WILLIAM H. STERNBERG, M.D. (From the Department of Pathology, School of Medicine, Tulane University of Louisiana and the Charity Hospital of Louisiana, New Orleans, La.) The hilus of the human ovary contains nests of cells morphologically identical with testicular Leydig cells, and which, in all probability, pro- duce androgens. Multiple sections through the ovarian hilus and meso- varium will reveal these small nests microscopically in at least 8o per cent of adult ovaries; probably in all adult ovaries if sufficient sections are made. Although they had been noted previously by a number of authors (Aichel,l Bucura,2 and von Winiwarter 3"4) who failed to recog- nize their significance, Berger,5-9 in 1922 and in subsequent years, pre- sented the first sound morphologic studies of the ovarian hilus cells. Nevertheless, there is comparatively little reference to these cells in the American medical literature, and they are not mentioned in stand- ard textbooks of histology, gynecologic pathology, nor in monographs on ovarian tumors (with the exception of Selye's recent "Atlas of Ovarian Tumors"10). The hilus cells are found in clusters along the length of the ovarian hilus and in the adjacent mesovarium. They are, almost without excep- tion, found in contiguity with the nonmyelinated nerves of the hilus, often in intimate relationship to the abundant vascular and lymphatic spaces in this area. Cytologically, a point for point correspondence with the testicular Leydig cells can be established in terms of nuclear and cyto- plasmic detail, lipids, lipochrome pigment, and crystalloids of Reinke. -
(CD-P-PH/PHO) Report Classification/Justifica
COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82 -
Lysochrome Dyes Sudan Dyes, Oil Red Fat Soluble Dyes Used for Biochemical Staining of Triglycerides, Fatty Acids, and Lipoproteins Product Description
FT-N13862 Lysochrome dyes Sudan dyes, Oil red Fat soluble dyes used for biochemical staining of triglycerides, fatty acids, and lipoproteins Product Description Name : Sudan IV Other names: Sudan R, C.I. Solvent Red 24, C.I. 26105, Lipid Crimson, Oil Red, Oil Red BB, Fat Red B, Oil Red IV, Scarlet Red, Scarlet Red N.F, Scarlet Red Scharlach, Scarlet R Catalog Number : N13862, 100g Structure : CAS: [85-83-6] Molecular Weight : MW: 380.45 λabs = 513-529 nm (red); Sol(EtOH): 0.09%abs =513-529nm(red);Sol(EtOH):0.09% S:22/23/24/25 Name : Sudan III Other names: Rouge Sudan ; rouge Ceresin ; CI 26100; CI Solvent Red 23 Catalog Number : 08002A, 25g Structure : CAS:[85-86-9] Molecular Weight : MW: 352.40 λabs = 513-529 nm (red); Sol(EtOH): 0.09%abs =503-510nm(red);Sol(EtOH):0.15% S:24/25 Name : Sudan Black B Other names: Sudan Black; Fat Black HB; Solvent Black 3; C.I. 26150 Catalog Number : 279042, 50g AR7910, 100tests stain for lipids granules Structure : CAS: [4197-25-5] S:22/23/24/25 Molecular Weight : MW: 456.54 λabs = 513-529 nm (red); Sol(EtOH): 0.09%abs=596-605nm(blue-black) Name : Oil Red O Other names: Solvent Red 27, Sudan Red 5B, C.I. 26125 Catalog Number : N13002, 100g Structure : CAS: [1320-06-5 ] Molecular Weight : MW: 408.51 λabs = 513-529 nm (red); Sol(EtOH): 0.09%abs =518(359)nm(red);Sol(EtOH): moderate; Sol(water): Insoluble S:22/23/24/25 Storage: Room temperature (Z) P.1 FT-N13862 Technical information & Directions for use A lysochrome is a fat soluble dye that have high affinity to fats, therefore are used for biochemical staining of triglycerides, fatty acids, and lipoproteins. -
An Improved Method of Staining Lipides : - Acetic- Carbol - Sudan
. Onderstepoort J ournal of Vetet·inary Science and Animal l ndustrJJ, Volu-me 19, Nmnbers 1 and 2, Jamwry and April, 1944. Printed in the Union of South Africa by the Government Printer, Pretoria. An Improved Method of Staining Lipides : - Acetic- Carbol - Sudan. By CECIL JACKSON, Section of Anatomy, Onderstepoort. INTRODUCTION. THE literature on the microscopical demonstration of fats and fat-like substances is largely a record of dissatisfaction with previous methods. It is noteworthy how many authors, investigating the lipides of normal or patho logical tissues, have felt impelled to turn their attention to imprpvement of technique. Some of these have gone_ further and have become absorbed in the problem of fat-staining for its own sake and apart from the difficulties they originally encountered. 'l'he technique of Sudan staining is essentially a physico-chemical prqblem and histologist§ or pathologists venturing into this realm have sometimes had to run the gauntlet of expert criticism. This danger may act as a deterrent to investigation; but it is comforting to reflect that a successful technique will stand up to a lot of argument about its rationale: a good method will remain, irrespective of the ability of its author to defend or explain the theory underlying it, Many attempts have been made, either to modify the methods of using existing dyes or to introduce new dyes in the hope of securing improvement in fat staining. Thus we have seen " Sudan III ", " Scharlach R ", and " Sudan IV " successively become _the favourite or at least the most highly recommended substances; and there are a number of technical variations depending on the solvents used or on the -procedure of making the dilutions from stock solutions. -
Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide -
Hyaluronic Acid Introduced 2003
Hyaluronic Acid Introduced 2003 What Is It? Are There Any Potential Drug Interactions? Hyaluronic acid, or HA, is a naturally occurring polymer found in every tissue of At this time, there are no known adverse reactions when taken in conjunction the body. It is particularly concentrated in the skin (almost 50% of all HA in the with medications. body is found in the skin) and synovial fluid. It is composed of alternating units of n-acetyl-d-glucosamine and d-glucuronate. This polymer’s functions include Hyaluronic acid attracting and retaining water in the extracellular matrix of tissues, in layers of skin, and in synovial fluid.* each vegetarian capsule contains v 3 hyaluronic acid (low molecular weight) ..............................................................................70 mg Features Include other ingredients: hypo-allergenic plant fiber (cellulose), vegetarian capsule (cellulose, water) 1–2 capsules per day, in divided doses, with or between meals. Clinically Researched Absorption: In nature, HA is a large molecular weight compound, ranging in size from 500,000-6,000,000 daltons. This is too large to ® be absorbed in the small intestines. HyaMax sodium hyaluronate provides a Hyaluronic acid liquid low molecular weight source of hyaluronic acid produced through fermentation. ® In a pharmacokinetic study, orally administered HyaMax hyaluronic acid was 2 ml (0.06 fl oz) (2 full droppers) contains v incorporated into joints, connective tissue and skin, with a particular affinity for hyaluronic acid (low molecular weight) ..............................................................................10 mg cartilaginous joints.* other ingredients: purified water, apple juice concentrate, citric acid, natural apple flavor, potassium sorbate, purified stevia extract Uses For Hyaluronic Acid serving size: 2 ml (0.06 fl oz) Skin Health: For skin cells, the ability of HA to attract and retain water is servings per container: 29 essential for proper cell-to-cell communication, hydration, nutrient delivery, and 1-2 servings daily, with or between meals. -
How to Construct and Use a Simple Device to Prevent the Formation of Precipitates When Using Sudan Black B for Histology
Acta Botanica Brasilica 29(4): 489-498. 2015. doi: 10.1590/0102-33062015abb0093 How to construct and use a simple device to prevent the formation of precipitates when using Sudan Black B for histology João Marcelo Santos de Oliveira1 Received: April 17, 2015. Accepted: July 1, 2015 ABSTRACT The present work aims to demonstrate the stages of fabrication and use of a simple device to avoid the formation or fixa- tion of precipitates from Sudan Black B solution on tissues. The device consists of four coverslip fragments attached to a histology slide, which serve as points of support for the histological slide under analysis. To work properly, the histology slide with the sections should be placed with the sections facing downwards the device. A small space between the device and the histology slide is thereby created by the height of the coverslip fragments. When Sudan Black B is applied, the solution is maintained within the edges of the device and evaporation is minimized by the small space, thereby reducing the consequent formation of precipitates. Furthermore, by placing the sections facing downward the device, any sporadically formed precipitates are prevented from settling on and fixing to the sectioned tissues or organs. By avoiding the formation of precipitates, plant cells, tissues and organs can be better observed, diagnosed and photomicrographically recorded. Keywords: histochemical tests, histology, lipids, plant anatomy, Sudan Black B Introduction for organic solvents, printer ink, varnishes, resins, oils, fats, waxes, cosmetics and contact lenses. Sudan reagents, including the traditional Sudan III, IV Lansink (1968) isolated two pure fractions of Sudan and Sudan Black B (SBB), are widely utilized to determine Black B, in addition to impurities, and denominated them lipids (Horobin 2002) in animals, plants and hydrophobic SBB-I and SBB-II. -
A Method for Staining Whole Brains for Gross and Macroscopic Study by W
[ 134 ] A METHOD FOR STAINING WHOLE BRAINS FOR GROSS AND MACROSCOPIC STUDY BY W. HEWITT Department of Anatomy, St Thomas's Hospital Medical School, London A number of staining techniques are available for the macroscopic examination of thick slices of brain. Examples are those of Mulligan (1931) or Tompsett (1955), which stain the grey matter; or those of Waldman & Michaels (1954) or Brody & Wirth (1957), which colour the white matter with sudan stains. In all of these only the surface of a previously cut slice is stained and surface staining has a number of disadvantages. The techniques of Mulligan (1931) and Tompsett (1955) require a painstaking removal of the membranes and blood vessels, before sections are cut, to prevent smearing of the grey and white matter. Even then success is by no means always assured. Surface-stained brain slices will also be spoilt, by exposure ofunstained areas underneath, if accidentally knocked or chipped. Moreover, the section originally made may not be the one desired and it is not possible to pare away the surface to the desired level. Apart from these disadvantages, it can be useful to stain a whole brain so that when it is sectioned the grey and white matter can be clearly distinguished. For these reasons a technique has been developed for staining a whole brain using sudan stains. This was devised before the writer was aware of the staining methods of Waldman & Michaels (1954) and Brody & Wirth (1957); it is in fact based on a different principle. METHOD The brains can be fixed in either 70 % alcohol or, for preference, 10 % formaldehyde. -
Sudan Dyes and Other Illegal Dyes
Sudan dyes and other illegal dyes Analysis in spices and food Sudan dyes, e.g. Sudan I to IV, Sudan In October 2004, the governmental Orange G, Sudan Red B, Sudan Red G, chemical institute “Bergisches Land” in Sudan Red 7B, and Sudan Black B as Wuppertal, Germany, reported the well as other dyes like 4-(Dimethylamino)- identification of two prohibited colours: azobenzene (Butter Yellow) and Para Butter Yellow and Para Red in bell pepper Red are basically synthetically produced powder and curry. azo dyes. Their degradation products are In February 2005, Great Britain experi- considered to be carcinogens and enced an extensive Rapid Alert action teratogens. Due to this fact, the EU does cycle. Due to the widespread use of one not permit the use of these colours as batch of chilli powder contaminated with food additives. However, in some Sudan I, batches of different products like countries, these dyes are still occasionally Worcester sauce, pizzas, pot noodles and used in order to intensify the colour of bell seafood sauces were subjected to com- pepper and chilli powder. plete recalls. Background Another recent concern is the discovery of the natural colour annatto in food and During 2003, the EU-Rapid Alert System spice mixes. Annatto (E 160b) is permit- (RASFF) issued a series of notifications ted by the EU for use in a variety of foods concerning the presence of Sudan dyes and beverages but not in spices and in chilli products and others such as spice mixtures. Its main colouring constit- spices, mixtures of spices, tomato uent is Bixin, with Norbixin being present sauces, pastas and sausages. -
Application of Standard Micro-Anatomical Staining Methods to Epoxy Resin-Embedded Sections
J Clin Pathol: first published as 10.1136/jcp.22.5.589 on 1 September 1969. Downloaded from J. clin. Path. (1969), 22, 589-592 Application of standard micro-anatomical staining methods to epoxy resin-embedded sections S. R. APARICIO AND P. MARSDEN From the Department ofPathology, School of Medicine, Leeds SYNOPSIS Staining of semi-thin sections of osmium-fixed epoxy resin (Epon or Araldite)-embedded tissues with haematoxylin and acid dyes as counterstains (eosin or phloxin) was successfully achieved after intense oxidation using hydrogen peroxide as the oxygen donor. Results are closely similar to those obtained with paraffin sections (haematoxylin and eosin): nuclei stain blue, cytoplasm and extracellular structures (eg, collagen, elastica, basement membranes) stain with varying shades of red. Preliminary studies show that similarly good results, comparable with standard paraffin- embedded histological materials, can be obtained, using H202 pretreatment, with Weigert's iron haematoxylin, Mallory's phosphotungstic acid haematoxylin, Alcian blue, PAS reaction, Sudan III, Sudan black, oil red, Gomori's aldehyde fuchsin, and Baker's acid haematein. Staining of semi-thin sections of osmium-fixed, since Epon and Araldite became universally adopted copyright. epoxy resin-embedded tissues was developed in as embedding media. the last decade, mainly using basic aniline dyes This communication reports a simple and efficient in neutral or alkaline solutions (Bencosme, Stone, method of obtaining haematoxylin-eosin and haema- Latta, and Madden, 1959; Moore, Mumaw, and toxylin-phloxin epoxy resin preparations identical Schoenberg, 1960; Richardson, Jarett, and Finke, in colour contrast with paraffin sections. 1960; Trump, Smuckler, and Benditt, 1961; Grimley, Albrecht, and Michelitch, 1965; Lee and Hopper, MATERIAL AND METHODS 1965; Aoki and Gutierrez, 1967; Aparicio and Mars- http://jcp.bmj.com/ den, 1969; Huber, Parker, and Odland, A variety of tissues (human brain, peripheral nerve, 1968). -
Bulk Drug Substances Under Evaluation for Section 503A
Updated July 1, 2020 Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act Includes three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Concerns • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Section 503A Categories • Removal from category 3 o Artesunate – This bulk drug substance is a component of an FDA-approved drug product (NDA 213036) and compounded drug products containing this substance may be eligible for the exemptions under section 503A of the FD&C Act pursuant to section 503A(b)(1)(A)(i)(II). This change will be effective immediately and will not have a waiting period. For more information, please see the Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A and the final rule on bulk drug substances that can be used for compounding under section 503A, which became effective on March 21, 2019. 1 Updated July 1, 2020 503A Category 1 – Bulk Drug Substances Under Evaluation • 7 Keto Dehydroepiandrosterone • Glycyrrhizin • Acetyl L Carnitine/Acetyl-L- carnitine • Kojic Acid Hydrochloride • L-Citrulline • Alanyl-L-Glutamine • Melatonin • Aloe Vera/ Aloe Vera 200:1 Freeze Dried • Methylcobalamin • Alpha Lipoic Acid • Methylsulfonylmethane (MSM) • Artemisia/Artemisinin • Nettle leaf (Urtica dioica subsp. dioica leaf) • Astragalus Extract 10:1 • Nicotinamide Adenine Dinucleotide (NAD) • Boswellia • Nicotinamide